Two patient advocacy groups have launched a legal challenge against the government over proposals to raise the price thresholds at which the NHS approves prescription drugs for routine use. Just Treatment and Global Justice Now wrote to ministers in recent weeks signalling their intent to seek judicial review, arguing the changes carry significant financial consequences for the health service and were made without adequate procedural scrutiny.

The dispute concerns new regulations announced in December 2025 that would alter how the National Institute for Health and Care Excellence evaluates whether treatments represent good value for money. Under the current framework, NICE approves drugs that cost between £20,000 and £30,000 per Quality Adjusted Life Year, a measure that combines length and quality of life into a single figure. The proposed changes would raise that range to £25,000 and £35,000.

The practical effect of lifting those limits is to allow pharmaceutical companies to charge higher prices for new treatments while still satisfying the criteria for NHS adoption. Campaigners estimate this will add billions of pounds to annual drug spending, money they argue would otherwise fund staffing and services in a system already under sustained financial pressure.

The timing has attracted considerable attention. The changes were negotiated as part of a broader trade agreement with the administration of US President Donald Trump, concessions the government made to avoid punitive tariffs on British exports. Critics have argued this amounts to subordinating domestic health policy to international commercial interests.

The legal proceedings are expected to centre on two questions. The first is whether ministers followed the statutory requirements that govern major changes to NHS pricing and commissioning frameworks. The second is whether the financial implications for the health service were properly assessed and disclosed before the decision was taken.

A government spokesperson said the changes would allow NHS patients faster access to innovative treatments and that the overall value framework remained robust. The Department of Health has not confirmed whether it intends to contest the judicial review application, though legal proceedings of this kind typically prompt a formal defence from the relevant department.

If the challenge fails and the regulations come into effect, the NHS will face a structural shift in how it accounts for high-cost drugs. Treatments that were previously considered too expensive for routine prescription could become approvable, widening access in some areas. But independent health economists have cautioned that the cumulative cost of approving drugs at higher thresholds across the full range of treatments under appraisal could outpace any benefit, forcing compensatory reductions elsewhere in the system.

The case is likely to draw wider interest from those monitoring the relationship between trade policy and public services. While the government has consistently framed the agreement with Washington as a net gain for the British economy, opponents contend that NHS pricing concessions represent a structural cost that has not been adequately accounted for in those calculations.

Just Treatment has previously mounted legal challenges to government decisions on drug pricing and NHS access. Global Justice Now campaigns on trade and corporate accountability issues and has been vocal in its opposition to pharmaceutical provisions in trade agreements more broadly.

A hearing date for the judicial review application has not yet been confirmed. If leave is granted by the courts, a full hearing would likely follow later in the year. The outcome would carry implications not only for the immediate regulations but for how future governments negotiate healthcare provisions within international trade agreements.